The Patent Finder
BT

Bioverativ Therapeutics Inc.

First filing 2004
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Biogen Hemophilia Inc. (to 2017)

78 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Mar 2027
Next term end
40
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Factor IX Polypeptides and Methods of Use Thereof US 9,670,475
Cited by 84 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Ends Jul 2031 · Medium confidence
Also notable
Immunoglobulin Chimeric Monomer-Dimer Hybrids US 7,404,956
The most cited patent in this portfolio, cited by 238 later US patents, top 5% of utility patents granted in 2008 in our data. Protection runs to 2028.
Ends Jun 2028 · High confidence
Also notable
Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof US 9,050,318
Cited by 107 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Apr 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 9 to 27, 2026 · next Dec 9
  • 3 fees due Feb 6 to 27, 2027 · next Feb 6
  • 3 fees due Mar 5 to 24, 2027 · next Mar 5
  • 1 fee due Apr 17, 2027
    The maintenance fee for Optimized Factor VIII Gene (US 11,787,851) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 2 fees due Jul 12 to 26, 2027 · next Jul 12
  • 4 fees due Aug 4 to 25, 2027 · next Aug 4
  • 1 fee due Sep 17, 2027
    The maintenance fee for Factor IX Polypeptide Formulations (US 10,588,949) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
  • 1 fee due Oct 7, 2027
    The maintenance fee for On-Column Viral Inactivation Methods (US 10,611,794) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
  • 1 fee due Nov 19, 2027
    The maintenance fee for Assays to Monitor Bleeding Disorders (US 10,656,167) comes due Nov 19, 2027. Unpaid by May 19, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

What they patent

The largest of its 40 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,795,400PC5 as a Factor IX Propeptide Processing Enzyme
In force
 · Medium confidence
In forceMedium confidence
US 8,021,880PC5 as a Factor IX Propeptide Processing Enzyme
In force
 · Medium confidence
In forceMedium confidence
US 7,566,565PC5 as a Factor IX Propeptide Processing Enzyme
In force
 · High confidence
In forceHigh confidence
US 7,348,004Immunoglobulin Chimeric Monomer-Dimer Hybrids
In force
 · High confidence
In forceHigh confidence
US 7,404,956Immunoglobulin Chimeric Monomer-Dimer Hybrids
In force
 · High confidence
In forceHigh confidence
US D741,703Package
In force
 · High confidence
In forceHigh confidence
US D751,705Syringe
In force
 · High confidence
In forceHigh confidence
US 9,050,318Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 11,266,720Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,241,978Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 78 patents shown.
Pro members see all 78.
Pro members: see all 78 patents
Also on record, not counted in the 78: 5 patents in force now held by others · 17 patents ended · 34 applications pending · 51 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited